ClinicalTrials.gg
CompletedNCT04020406Updated Jul 16, 2019

Antibacterial Activity of Urea Against Ocular Bacteria

An observational study in Urea in Blood; High, sponsored by Assiut University. Completed at 1 site in Egypt. Open to participants aged 5 Months to 65 Years. Per ClinicalTrials.gov, last updated 2019-07-16.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Ages
5 Months to 65 Years
Sex
All
01

Study summary

Antibacterial properties of urea was tested against 35 isolates from ocular infections.

Read the detailed description

In vitro susceptibility testing was performed with commercially available antibiotic discs, homemade urea discs saturated with urea solution at a concentration of 96 mmol. The weight of urea in one drop = 0.37 mg, in one ml = 10.34 mg (5 microliter/ disc) discs and combined discs (antibiotic discs to which urea solution was added). Combined discs provided better in vitro susceptibility results than antibiotics alone.

Scanning electron micrographs of bacterial isolates incubated overnight with urea solution showed marked disruption of bacterial aggregative patterns and irregularities of their cell walls.

Western blotting showed marked reduction in total proteins in bacterial isolates incubated overnight with urea solution. These findings may explain the possible mechanisms for antibacterial activity of urea solution as a result of protein denaturation.

02

Conditions studied

  • Urea in Blood; High

Browse trials for

03

In context

Uremia

53 studies on the registry are indexed under Uremia; 10 are open to participants now.

This study's enrollment of 90 is below the median of 105 across 12 observational studies indexed under Uremia.

Browse Uremia studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Months to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

individuals with any ocular infection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ocular infection

Exclusion criteria

Exclusion Criteria:

  • Local antibiotics treatment
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (actual)
Patient registry
No

Groups and cohorts

  • Antibacterial Activity of Urea

    Activity of Urea Solution against Ocular Bacterial Isolates

    Biological: Antibacterial Activity

Interventions

  • BiologicalAntibacterial Activity

    Antibacterial Activity of Urea Solution against Ocular Bacterial Isolates

06

What researchers measure

Primary outcomes

  1. Antibacterial effect of Urea Solution against Ocular Bacterial

    Samples were both inoculated on Muller Agar (Sigma-Aldrich) plates and directly examined under the microscope using Gram stained smears. Inoculated plates were incubated at 37oC for 48 hrs. Gram negative isolates were sub-cultured on MacConkey's, Eosin Methelyene Blue (EMB) and Cystine Lactose Electrolyte Deficient (CLED) agar plates (Sigma-Aldrich). Gram positive isolates were sub-cultured on Mannitol Salt agar plates (Sigma-Aldrich).

    Time frame: 6 month

07

Study locations

1 site
  • Hassan Lotfy Fahmy
    Assiut, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Nov 2018, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2019
First posted
Jul 16, 2019
StartActual
Nov 1, 2017
Primary completionActual
Nov 1, 2018
CompletionActual
Nov 1, 2018
Last update
Jul 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04020406
Lead sponsor
Assiut University
Responsible party
Hassan Lotfy Fahmy (Clinical Professor, Assiut University) — Principal investigator
First posted
Jul 16, 2019
Start date
Nov 1, 2017
Primary completion
Nov 1, 2018
Completion
Nov 1, 2018
Last update
Jul 16, 2019

Study contacts

Hassan 58 Lotfy, Professor
principal investigator · Assiut T

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion